Abstract
AbstractThe desire to find a gold-standard therapy for depression is still ongoing. Developing one universal and effective pharmacotherapy remains troublesome due to the high complexity and variety of symptoms. Over the last decades, the understanding of the mechanism of pathophysiology of depression and its key consequences for brain functioning have undergone significant changes, referring to the monoaminergic theory of the disease. After the breakthrough discovery of ketamine, research began to focus on the modulation of glutamatergic transmission as a new pharmacological target. Glutamate is a crucial player in mechanisms of a novel class of antidepressants, including hallucinogens such as ketamine. The role of glutamatergic transmission is also suggested in the antidepressant (AD) action of scopolamine and psilocybin. Despite fast, robust, and sustained AD action hallucinogens belonging to a group of rapid-acting antidepressants (RAA) exert significant undesired effects, which hamper their use in the clinic. Thus, the synergistic action of more than one substance in lower doses instead of monotherapy may alleviate the likelihood of adverse effects while improving therapeutic outcomes. In this review, we explore AD-like behavioral, synaptic, and molecular action of RAAs such as ketamine, scopolamine, and psilocybin, in combination with mGlu2/3 receptor antagonists.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology,General Medicine
Reference76 articles.
1. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):655–79.
2. Nirmita Panchal RK, Cynthia Cox, Rachel Garfield. The Implications of COVID-19 for Mental Health and Substance Use. wwwkfforg/coronavirus-covid-19/issue-brief/the-implications-of-covid-19-for-mental-health-and-substance-use. 2021.
3. Healy D. The antidepressant era. Cambridge: Harvard University Press; 1999.
4. Podkowa K, Pochwat B, Branski P, Pilc A, Palucha-Poniewiera A. Group II mGlu receptor antagonist LY341495 enhances the antidepressant-like effects of ketamine in the forced swim test in rats. Psychopharmacology. 2016;233(15–16):2901–14.
5. Clinicaltrials.gov. NCT03386448: the safety and efficacy of naltrexone and scopolamine utilized in the treatment of major depression. https://www.clinicaltrials.gov/study/NCT03386448.